MegaPro Biomedical Co. is invited to attend 2018 China BioMed Innovation and Investment Conference (CBIIC) and roadshow present.
Two clinical studies regarding IOP Injection nanomedicine has been completed by MegaPro. Two phase 2 clinical trials, one for iron deficient anemia and one for MRI contrast agent on HCC patients, has been approved by FDA and will be conducted at USA and Taiwan separately at October 2018. Dr. Jassy Wang, on behalf of MegaPro will present the company status at CBIIC Roadshow to introduce the results and company's future plan.

MPB1514 for iron Deficiency Anemia
MPB1514 is a nanomedicine with iron oxide as the core and PEGylation as the shell, to form a 40-80 nm nanoparticles. The advantages of MPB1514 are:

1. their high macrophage uptake efficiency, thus to make sufficient iron in the liver to favor ferritin and transferrin increasing

2. non-sugar excipient thus to lower the hypersensitivity occurrence.

MPB1523 as MRI contrast agent for Hepatocellular Carcinoma (HCC) patients
MPB1523 is a nanomedicine with supra-paramagnetic iron oxide as the core and PEGylation as the shell, to form a 40-80 nm nanoparticles. Because of the high macrophage uptake efficiency and r₂ relaxivity, MPB1523 can be used to identify liver tumor from HCC to Hemangioma in MRI image. It also can be used to trace lymph node metastasis by MRI diagnosis. Another advantage for using MPB1523 is to avoid potential toxic of traditional Gadolinium based contrast agent (GBCA) for nephrogenic systemic fibrosis (NSF) and brain deposition.

Regarding MegaPro Biomedical Co. Ltd.
MegaPro was established at 2015, a company focused at nanomedicines development. Two technology platforms, nano particles and nano micelles, has been developed by MegaPro. Currently, phase 2 on IDA and MRI contrast agent are conducted at USA and Taiwan separately. The nanomicelles for targeting anticancer drug is one the way for 505(b)(2) drug development. Welcome to visit MegaPro's website as following: http://www.megaprobio.com